OPENLANE (NYSE:KAR – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Barrington Research in a research report issued on Monday, Benzinga reports. They currently have a $25.00 target price on the specialty retailer’s stock. Barrington Research’s price target points to a potential upside of 54.13% from the company’s previous close.
OPENLANE Stock Up 2.0 %
Shares of KAR traded up $0.32 during mid-day trading on Monday, reaching $16.22. The company had a trading volume of 100,515 shares, compared to its average volume of 693,615. OPENLANE has a 52-week low of $12.86 and a 52-week high of $18.73. The stock has a market capitalization of $1.76 billion, a P/E ratio of 107.60, a PEG ratio of 1.66 and a beta of 1.44. The stock has a 50 day moving average of $16.43 and a two-hundred day moving average of $16.94.
OPENLANE (NYSE:KAR – Get Free Report) last issued its earnings results on Wednesday, August 7th. The specialty retailer reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.02). OPENLANE had a return on equity of 7.85% and a net margin of 3.39%. The company had revenue of $431.80 million during the quarter, compared to analysts’ expectations of $426.11 million. During the same quarter in the previous year, the company earned $0.25 EPS. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts expect that OPENLANE will post 0.77 earnings per share for the current year.
Hedge Funds Weigh In On OPENLANE
About OPENLANE
OPENLANE, Inc, together with its subsidiaries, operates as a digital marketplace for used vehicles, which connects sellers and buyers in North America, Europe, the Philippines, and Uruguay. The company operates through two segments, Marketplace and Finance. The Marketplace segment offers digital marketplace services for buying and selling used vehicles.
Read More
- Five stocks we like better than OPENLANE
- Industrial Products Stocks Investing
- Intel: Is Now the Time to Be Brave?Â
- Roth IRA Calculator: Calculate Your Potential Returns
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is the NASDAQ Stock Exchange?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for OPENLANE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPENLANE and related companies with MarketBeat.com's FREE daily email newsletter.